Promising NMOSD attack treatment trial pulled before starting
NCT ID NCT06673394
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study aimed to test whether eculizumab, a drug already approved to prevent NMOSD attacks, could also help treat acute attacks in adults with AQP4 antibodies. It was designed for people experiencing sudden optic nerve or spinal cord inflammation. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.